Development of Non-invasive Prenatal Test for Microdeletion and Other Genetic Syndromes Based on Cell Free DNA

NCT02109770 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 216

Last updated 2019-08-26

No results posted yet for this study

Summary

The purpose of this study is to collect blood from families with a child who has been diagnosed with a chromosomal disorder including microdeletions in order to further develop a non-invasive prenatal screening test based on fetal DNA isolated from maternal blood.

Conditions

  • Microdeletion Syndromes
  • Trisomy 21
  • Trisomy 18
  • Trisomy 13
  • Sex Chromosome Abnormalities

Sponsors & Collaborators

  • Natera, Inc.

    lead INDUSTRY

Principal Investigators

  • Kim Martin, MD · Natera, Inc.

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-10-31
Primary Completion
2019-06-30
Completion
2019-08-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02109770 on ClinicalTrials.gov